NCT05062200 is a Phase 1 clinical trial of JNJ-77242113 in Healthy, sponsored by Janssen Pharmaceutical K.K..

Who is sponsoring NCT05062200?

NCT05062200 is sponsored by Janssen Pharmaceutical K.K..

What drugs are being tested in NCT05062200?

Interventions in NCT05062200: JNJ-77242113, Placebo.

Is NCT05062200 still recruiting?

NCT05062200 is currently completed. Last updated 3 February 2025.

Last reviewed 2025-02-03 · How we verify

NCT05062200

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants

Completed Phase 1 Last updated 3 February 2025

What this trial tests

Phase 1 trial testing JNJ-77242113 in Healthy in 36 participants. Completed in 28 September 2022.

Timeline

25 October 2021

Primary endpoint
28 September 2022

28 September 2022

Quick facts

Lead sponsor	Janssen Pharmaceutical K.K.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	treatment
Enrollment	36
Start date	25 October 2021
Primary completion	28 September 2022
Estimated completion	28 September 2022
Sites	1 location across Japan

Drugs / interventions tested

JNJ-77242113 — full drug profile →
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Janssen Pharmaceutical K.K. — full company profile →

Who can join

Adults 20 to 60, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of JNJ-77242113 after single ascending oral dose administration as an immediate-release (IR) tablet formulation in healthy Japanese participants and after single oral dose administration as an IR tablet formulation in healthy Chinese participants; and as a delayed release (DR) tablet formulation in healthy Japanese participants.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis.
Carmona-Rocha E, Rusiñol L, Puig L. · · 2024 · cited 28× · PMID 38399292 · DOI 10.3390/pharmaceutics16020239
Oral Peptide Therapeutics as an Emerging Treatment Modality in Immune-Mediated Inflammatory Diseases: A Narrative Review.
Stein Gold L, Eyerich K, Merola JF, Torres J, et al · · 2025 · cited 7× · PMID 40439953 · DOI 10.1007/s12325-025-03213-8

Verify or expand the search:

Other trials of JNJ-77242113

Trials testing the same drug.

NCT06934226 — A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate · Phase 3 · active not recruiting
NCT06220604 — A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) · Phase 3 · active not recruiting
NCT06295692 — A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis · Phase 3 · active not recruiting
NCT06143878 — A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis · Phase 3 · active not recruiting
NCT06095102 — A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, · Phase 3 · active not recruiting

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Janssen Pharmaceutical K.K. trials

Trials by the same sponsor.

NCT06295692 — A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis · Phase 3 · active not recruiting
NCT05926583 — A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa · Phase 3 · active not recruiting
NCT05567185 — A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer · Phase 1 · active not recruiting
NCT05167825 — A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension · Phase 3 · completed
NCT05242432 — A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05062200 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Pharmaceutical K.K.
Last refreshed: 3 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05062200.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing